Abstract
Nelarabine is a prodrug of the deoxyguanosine analogue, 9-β-D-arabinofuranose guanine (ara-G), which is used for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). For the clinical study of nelarabine and its active ingredient, ara-G, a suitable isotope-labeled internal standard was required. Effective and operationally simple methods for the synthesis of [D4]]nelarabine and [D3]ara-G were developed with high deuterium incorporation using D2O, CD3OD and NaBD4 as deuterium sources. It was found that [D3]ara-G was useful as an internal standard instead of [D4]nelarabine. Nelarabine is a prodrug of the deoxyguanosine analogue, 9-β-D-arabinofurose guanine (ara-G), which is used for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). For the clinical study of nelarabine and its active ingredient, ara-G, a suitable isotope-labeled internal was not suitable as an internalstandard was required. Effective and operationally simple methods for the synthesis of [D4]]nelarabine and [D3]ara-G were developed with high deuterium incorporation using D2O, CD3OD and NaBD4 as deuterium sources. It was found that [D3]ara-G was useful as an internal standard instead of [D4 ]nelarabine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
